Medication info
Rinacombi Sustained Release Tablet 5/1000 mg (Linagliptin, Metformin)

Rinacombi Sustained Release Tablet 5/1000 mg (Linagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletLinagliptin Micronized›5mg / 1 tablet
Manufacturer / importer
Aprogen Biologics, Co., Ltd.
Appearance
White, oval, sustained-release film-coated tablet imprinted with AI 5/1000 on one side
Packaging
28 tablets (7 tablets/PTPX4) / box, 30 tablets / bottle, 100 tablets / bottle
Approval status
Active

MFDS item code 202400574 · Approved 2024.03.19 · Insurance code 645210910

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride (extended-release) 2000 mg. Take this medicine once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Take one 5/1000 mg extended-release tablet once daily. Patients taking the 2.5/1000 mg extended-release tablet should take two tablets at the same time once daily. 1. Patients not currently receiving metformin: The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with metformin plus a sulfonylurea or metformin plus insulin, the initial dose of this medicine should be considered as a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose. When this medicine is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine is the patient's current dose of linagliptin and extended-release metformin hydrochloride. No dosage adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) ≥ 45mL/min and < 60mL/min or estimated glomerular filtration rate (eGFR) ≥ 45mL/min/1.73m2 and < 60mL/min/1.73m2, this medicine may be used with metformin hydrochloride dose adjustment as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to < 45mL/min or estimated glomerular filtration rate (eGFR) decreases to < 45mL/min/1.73m2, discontinue this medicine immediately.

Ingredients

Manufacturer
Aprogen Biologics, Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication helps improve blood sugar control in patients with type 2 diabetes who require a combination of linagliptin and metformin, supplementing dietary and exercise therapies.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride (extended-release) 2000 mg. Take this medicine once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Take one 5/1000 mg extended-release tablet once daily. Patients taking the 2.5/1000 mg extended-release tablet should take two tablets at the same time once daily. 1. Patients not currently receiving metformin: The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with metformin plus a sulfonylurea or metformin plus insulin, the initial dose of this medicine should be considered as a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose. When this medicine is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine is the patient's current dose of linagliptin and extended-release metformin hydrochloride. No dosage adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) ≥ 45mL/min and < 60mL/min or estimated glomerular filtration rate (eGFR) ≥ 45mL/min/1.73m2 and < 60mL/min/1.73m2, this medicine may be used with metformin hydrochloride dose adjustment as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to < 45mL/min or estimated glomerular filtration rate (eGFR) decreases to < 45mL/min/1.73m2, discontinue this medicine immediately.

Precautions

This medication assists in blood sugar control, and one of its active ingredients, metformin, can rarely cause a dangerous condition called lactic acidosis. Lactic acidosis occurs when there is an excessive buildup of lactic acid in the body, and if not treated immediately, it can be life-threatening. This medication should not be used in certain patients. For instance, it should not be given to those who are allergic to this medication or its components, patients with type 1 diabetes, patients with severe kidney dysfunction, patients with acute infections or serious trauma, patients with liver dysfunction, patients suffering from acute alcohol intoxication, patients with severely poor nutritional status, or pregnant women. This medication may cause hypoglycemia, and caution should be exercised, especially when used in conjunction with other hypoglycemic agents or insulin. Additionally, if lactic acidosis is suspected, this medication should be stopped immediately and medical attention sought. Before treatment initiation and during treatment, kidney function should be regularly monitored; if kidney function is impaired, this medication should not be used. Patients with poor heart function should also use this medication with caution. When taking this medication, use of iodinated contrast media for radiological tests or surgeries should involve a temporary discontinuation prior, and the medication should be resumed only after normal kidney function is confirmed. Adverse reactions such as acute pancreatitis or vesicular skin disorders may occur during treatment, and if persistent abdominal pain or skin vesicles develop, the patient should inform their doctor immediately. Side effects of this medication may include gastrointestinal symptoms (abdominal pain, diarrhea, nausea, vomiting, etc.), hypoglycemia, skin rash, liver dysfunction, muscle pain, etc., and vitamin B12 deficiency may occur, so regular monitoring is required with prolonged use. This medication should be swallowed whole and not chewed or crushed, although the tablet coating may appear in the feces, which is normal. When taken with other medications, interactions may occur, thus careful management in accordance with a doctors instructions is necessary, especially with drugs affecting kidney function or hypoglycemic agents. It is generally advisable not to use this medication during pregnancy or breastfeeding, and its safety and efficacy in children have not been established. Elderly patients may have decreased kidney function, so dosage adjustments and regular monitoring of kidney function are required. In the event of an overdose, steps should be taken to ensure the drug is not fully absorbed from the gastrointestinal tract, and if necessary, treatment may involve dialysis to remove the drug. This medication should be stored out of reach of children, in a moisture-free environment, and not transferred to another container.

Side effects

  • Severe lactic acidosis
  • hypoglycemia
  • angioedema
  • urticaria
  • lactic acidosis
  • abnormal vitamin B12 absorption test
  • hypoglycemia
  • taste disorder
  • cough
  • decreased appetite
Show 117 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • dermatitis herpetiformis
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • nasopharyngitis
  • hypersensitivity reaction
  • constipation
  • epigastric pain
  • enterocolitis
  • intestinal obstruction
  • gastritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • stuttering
  • Alzheimer's type dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot disease
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • renal transplant failure
  • anxiety
  • affective disorder
  • insomnia
  • depression
  • bruise
  • bone bruise
  • concussion
  • bone fracture
  • hand fracture
  • palpitations
  • dry eye
  • glaucoma
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • polyuria
  • proteinuria
  • stress urinary incontinence
  • hematuria
  • hypotension
  • flushing
  • hepatic steatosis
  • cholelithiasis
  • hearing loss
  • erectile dysfunction
  • goiter
  • anemia
  • nausea
  • gastroesophageal reflux disease
  • gastritis
  • dizziness
  • sensory loss
  • chest discomfort
  • weakness
  • pain
  • nosebleed
  • oropharyngeal pain
  • speech disorder
  • epistaxis
  • rhinorrhea
  • male pattern baldness
  • hyperhidrosis
  • hair loss
  • dermatitis
  • anxiety
  • confusional state
  • nocturia
  • dermatitis
  • hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. The recommended storage temperature is between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

White, oval, sustained-release film-coated tablet imprinted with AI 5/1000 on one side

Package unit

28 tablets (7 tablets/PTPX4) / box, 30 tablets / bottle, 100 tablets / bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.